

Amalio Telenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/617690/publications.pdf>

Version: 2024-02-01

268
papers

34,096
citations

4641

85
h-index

4628

170
g-index

298
all docs

298
docs citations

298
times ranked

38446
citing authors

#	ARTICLE	IF	CITATIONS
1	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , 2020, 583, 290-295.	13.7	1,695
2	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 387-402.	3.8	1,239
3	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. <i>Science</i> , 2007, 317, 944-947.	6.0	1,136
4	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. <i>Science</i> , 2010, 330, 1551-1557.	6.0	1,054
5	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	13.7	917
6	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet, The</i> , 1999, 353, 863-868.	6.3	894
7	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
8	Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. <i>Aids</i> , 2001, 15, 71-75.	1.0	743
9	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 321.	3.8	732
10	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. <i>Nature Genetics</i> , 2007, 39, 733-740.	9.4	691
11	Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. <i>Nature Immunology</i> , 2010, 11, 1127-1135.	7.0	644
12	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , 2002, 359, 30-36.	6.3	635
13	Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors. <i>Circulation</i> , 1999, 100, 700-705.	1.6	592
14	A primer on deep learning in genomics. <i>Nature Genetics</i> , 2019, 51, 12-18.	9.4	542
15	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541
16	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	10.6	485
17	The fecal metabolome as a functional readout of the gut microbiome. <i>Nature Genetics</i> , 2018, 50, 790-795.	9.4	482
18	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 410.	3.8	428

#	ARTICLE	IF	CITATIONS
19	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 1999, 282, 2220.	3.8	416
20	The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Medicine, 1997, 3, 567-570.	15.2	405
21	Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nature Biotechnology, 1998, 16, 359-363.	9.4	393
22	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science, 2021, 373, 648-654.	6.0	385
23	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021, 597, 97-102.	13.7	385
24	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	1.5	377
25	Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nature Genetics, 2017, 49, 568-578.	9.4	341
26	Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature, 2011, 472, 495-498.	13.7	328
27	Cohort Profile: The Swiss HIV Cohort Study. International Journal of Epidemiology, 2010, 39, 1179-1189.	0.9	322
28	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, The, 2001, 358, 1322-1327.	6.3	317
29	Deep sequencing of 10,000 human genomes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11901-11906.	3.3	315
30	Discontinuation of Primary Prophylaxis against Pneumocystis carinii Pneumonia in HIV-1-Infected Adults Treated with Combination Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1301-1306.	13.9	271
31	HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nature Genetics, 2009, 41, 1290-1294.	9.4	265
32	HIV entry inhibitors. Lancet, The, 2007, 370, 81-88.	6.3	264
33	Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science, 2021, 373, 1109-1116.	6.0	262
34	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	13.7	260
35	The blood DNA virome in 8,000 humans. PLoS Pathogens, 2017, 13, e1006292.	2.1	259
36	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065.	1.5	242

#	ARTICLE	IF	CITATIONS
37	Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy. <i>Aids</i> , 2001, 15, 329-334.	1.0	241
38	Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. <i>Cell Metabolism</i> , 2019, 29, 488-500.e2.	7.2	235
39	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 20-30.	2.3	231
40	The Human Microbiome and Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 226-234.	0.7	230
41	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021, 598, 342-347.	13.7	230
42	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
43	Crystal structure of GyrA intein from <i>Mycobacterium xenopi</i> reveals structural basis of protein splicing. <i>Nature Structural Biology</i> , 1998, 5, 31-36.	9.7	217
44	Human gene essentiality. <i>Nature Reviews Genetics</i> , 2018, 19, 51-62.	7.7	213
45	Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity. <i>Cell Host and Microbe</i> , 2016, 19, 504-514.	5.1	211
46	Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. <i>BMJ: British Medical Journal</i> , 1999, 319, 23-24.	2.4	208
47	Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides. <i>PLoS Biology</i> , 2012, 10, e1001448.	2.6	208
48	SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. <i>Blood</i> , 2014, 123, 1021-1031.	0.6	205
49	Genotypic Analysis of <i>Mycobacterium tuberculosis</i> in Two Distinct Populations Using Molecular Beacons: Implications for Rapid Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 103-110.	1.4	195
50	HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice. <i>Science</i> , 1998, 280, 1871-1873.	6.0	187
51	APOBEC3G Genetic Variants and Their Influence on the Progression to AIDS. <i>Journal of Virology</i> , 2004, 78, 11070-11076.	1.5	178
52	Paternally inherited cis-regulatory structural variants are associated with autism. <i>Science</i> , 2018, 360, 327-331.	6.0	174
53	Evolutionary and Functional Analyses of the Interaction between the Myeloid Restriction Factor SAMHD1 and the Lentiviral Vpx Protein. <i>Cell Host and Microbe</i> , 2012, 11, 205-217.	5.1	169
54	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011, 121, 2391-2400.	3.9	168

#	ARTICLE	IF	CITATIONS
55	Lausannevirus, a giant amoebal virus encoding histone doublets. <i>Environmental Microbiology</i> , 2011, 13, 1454-1466.	1.8	164
56	Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals. <i>PLoS Pathogens</i> , 2010, 6, e1000781.	2.1	158
57	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14658-14663.	3.3	154
58	WGAVIEWER: Software for genomic annotation of whole genome association studies: Figure 1.. <i>Genome Research</i> , 2008, 18, 640-643.	2.4	147
59	Profiling of Short-Tandem-Repeat Disease Alleles in 12,632 Human Whole Genomes. <i>American Journal of Human Genetics</i> , 2017, 101, 700-715.	2.6	142
60	Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. <i>Aids</i> , 2007, 21, 441-446.	1.0	139
61	Mutation position and type of substitution in the β -subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 345-348.	1.3	138
62	The human noncoding genome defined by genetic diversity. <i>Nature Genetics</i> , 2018, 50, 333-337.	9.4	137
63	24 Hours in the Life of HIV-1 in a T Cell Line. <i>PLoS Pathogens</i> , 2013, 9, e1003161.	2.1	134
64	Hepatic Cyst Infection in Autosomal Dominant Polycystic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 1990, 65, 933-942.	1.4	132
65	Copy Number Variation of KIR Genes Influences HIV-1 Control. <i>PLoS Biology</i> , 2011, 9, e1001208.	2.6	132
66	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. <i>ELife</i> , 2013, 2, e01123.	2.8	126
67	Identification of individuals by trait prediction using whole-genome sequencing data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10166-10171.	3.3	118
68	Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8059-8064.	3.3	118
69	Comparison of phasing strategies for whole human genomes. <i>PLoS Genetics</i> , 2018, 14, e1007308.	1.5	118
70	Contribution of <i>kasA</i> Analysis to Detection of Isoniazid-Resistant <i>Mycobacterium tuberculosis</i> in Singapore. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2087-2089.	1.4	117
71	Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1209-1213.	0.5	117
72	Clinical Implications of <i>Mycobacterium kansasii</i> Species Heterogeneity: Swiss National Survey. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1240-1244.	1.8	117

#	ARTICLE	IF	CITATIONS
73	Identification of Misclassified ClinVar Variants via Disease Population Prevalence. <i>American Journal of Human Genetics</i> , 2018, 102, 609-619.	2.6	117
74	Severe viral respiratory infections in children with <i>IFIH1</i> loss-of-function mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8342-8347.	3.3	111
75	The Evolution and Biology of SARS-CoV-2 Variants. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a041390.	2.9	110
76	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. <i>PLoS Pathogens</i> , 2013, 9, e1003515.	2.1	109
77	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	2.1	108
78	HIV-1 Capture and Transmission by Dendritic Cells: The Role of Viral Glycolipids and the Cellular Receptor Siglec-1. <i>PLoS Pathogens</i> , 2014, 10, e1004146.	2.1	108
79	HIV-Protease Inhibitors Reduce Cell Adherence of <i>Candida Albicans</i> Strains by Inhibition of Yeast Secreted Aspartic Proteases. <i>Journal of Investigative Dermatology</i> , 1999, 113, 747-751.	0.3	107
80	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1967-1969.	1.0	107
81	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2006, 80, 11094-11104.	1.5	103
82	Transplacental passage of protease inhibitors at delivery. <i>Aids</i> , 2002, 16, 889-893.	1.0	102
83	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet</i> , The, 2003, 362, 877-878.	6.3	101
84	Predicting the mutational drivers of future SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2022, 14, eabk3445.	5.8	101
85	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 0, , .	13.7	101
86	Analysis of HIV-1 and CMV-specific memory CD4 T-cell responses during primary and chronic infection. <i>Blood</i> , 2002, 100, 1381-1387.	0.6	97
87	Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e132.	1.3	97
88	Microbial metagenome of urinary tract infection. <i>Scientific Reports</i> , 2018, 8, 4333.	1.6	93
89	Oral administration of a low dose of midazolam (75µg) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 237-46.	0.8	89
90	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	1.9	89

#	ARTICLE	IF	CITATIONS
91	HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells. <i>Retrovirology</i> , 2015, 12, 37.	0.9	85
92	LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. <i>PLoS Genetics</i> , 2014, 10, e1004196.	1.5	83
93	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 231-6.	0.8	82
94	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3801-3808.	1.4	82
95	Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2001, 75, 3291-3300.	1.5	79
96	Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression. <i>PLoS ONE</i> , 2010, 5, e11079.	1.1	78
97	Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. <i>Retrovirology</i> , 2015, 12, 41.	0.9	78
98	Innate immunogenetics: a tool for exploring new frontiers of host defence. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 531-542.	4.6	76
99	Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein. <i>Journal of Virology</i> , 2001, 75, 9644-9653.	1.5	73
100	Changes in renal function associated with indinavir. <i>Aids</i> , 1998, 12, F249-F254.	1.0	72
101	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 865-873.	0.8	70
102	CCL3L1 and HIV/AIDS susceptibility. <i>Nature Medicine</i> , 2009, 15, 1110-1112.	15.2	70
103	Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model. <i>PLoS Pathogens</i> , 2014, 10, e1004156.	2.1	70
104	Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers. <i>Journal of Virology</i> , 2011, 85, 3015-3019.	1.5	69
105	Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. <i>Lancet</i> , The, 2000, 355, 2217-2218.	6.3	67
106	Structure-Function Analyses Point to a Polynucleotide-Accommodating Groove Essential for APOBEC3A Restriction Activities. <i>Journal of Virology</i> , 2011, 85, 1765-1776.	1.5	67
107	Transcription Factor-Directed Re-wiring of Chromatin Architecture for Somatic Cell Nuclear Reprogramming toward trans-Differentiation. <i>Molecular Cell</i> , 2019, 76, 453-472.e8.	4.5	67
108	Orosomucoid (α 1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 307-318.	2.3	66

#	ARTICLE	IF	CITATIONS
109	Ranking of non-coding pathogenic variants and putative essential regions of the human genome. <i>Nature Communications</i> , 2019, 10, 5241.	5.8	65
110	Deep learning of genomic variation and regulatory network data. <i>Human Molecular Genetics</i> , 2018, 27, R63-R71.	1.4	64
111	In Vitro Whole-Genome Analysis Identifies a Susceptibility Locus for HIV-1. <i>PLoS Biology</i> , 2008, 6, e32.	2.6	63
112	Quantitative Blood Cultures in Candidemia. <i>Mayo Clinic Proceedings</i> , 1991, 66, 1120-1123.	1.4	62
113	HIV-1 co/super-infection in intravenous drug users. <i>Aids</i> , 2004, 18, 1413-1421.	1.0	62
114	Genomics meets HIV-1. <i>Nature Reviews Microbiology</i> , 2006, 4, 865-873.	13.6	62
115	Analysis of HIV-1 Expression Level and Sense of Transcription by High-Throughput Sequencing of the Infected Cell. <i>Journal of Virology</i> , 2011, 85, 6205-6211.	1.5	62
116	<i>scell</i> : an R/Bioconductor package for statistical assessment of cell-state hierarchies from single-cell RNA-seq. <i>Bioinformatics</i> , 2015, 31, 3380-3382.	1.8	61
117	Infrequent Transmission of HIV-1 Drug-Resistant Variants. <i>Antiviral Therapy</i> , 2004, 9, 375-384.	0.6	59
118	Use of a Combined Ex Vivo/In Vivo Population Approach for Screening of Human Genes Involved in the Human Immunodeficiency Virus Type 1 Life Cycle for Variants Influencing Disease Progression. <i>Journal of Virology</i> , 2005, 79, 12674-12680.	1.5	56
119	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011, 53, 1446-1454.	3.6	56
120	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	2.9	56
121	Human Immunodeficiency Virus Type 1 Fitness Is a Determining Factor in Viral Rebound and Set Point in Chronic Infection. <i>Journal of Virology</i> , 2003, 77, 13146-13155.	1.5	54
122	Model Structure of Human APOBEC3G. <i>PLoS ONE</i> , 2007, 2, e378.	1.1	53
123	Disentangling Human Tolerance and Resistance Against HIV. <i>PLoS Biology</i> , 2014, 12, e1001951.	2.6	53
124	Identifying Adverse Effects of HIV Drug Treatment and Associated Sentiments Using Twitter. <i>JMIR Public Health and Surveillance</i> , 2015, 1, e7.	1.2	53
125	Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Inpatient Variability. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 394-398.	1.0	52
126	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006, 20, 889-894.	1.0	52

#	ARTICLE	IF	CITATIONS
127	Analysis of Natural Variants of the Human Immunodeficiency Virus Type 1 gag-pol Frameshift Stem-Loop Structure. <i>Journal of Virology</i> , 2002, 76, 7868-7873.	1.5	51
128	Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints. <i>Retrovirology</i> , 2011, 8, 87.	0.9	51
129	Evolutionary Trajectories of Primate Genes Involved in HIV Pathogenesis. <i>Molecular Biology and Evolution</i> , 2009, 26, 2865-2875.	3.5	50
130	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , 2000, 14, 1291.	1.0	50
131	GENETICS OF DRUG RESISTANCE IN TUBERCULOSIS. <i>Clinics in Chest Medicine</i> , 1997, 18, 55-64.	0.8	49
132	Drug-Resistant Tuberculosis. <i>Drugs</i> , 2000, 59, 171-179.	4.9	48
133	Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 511-522.	1.0	47
134	Entry and Transcription as Key Determinants of Differences in CD4 T-Cell Permissiveness to Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2004, 78, 10747-10754.	1.5	46
135	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010, 59, 1252-1258.	6.1	46
136	Safety concerns about CCR5 as an antiviral target. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 131-135.	1.5	45
137	A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. <i>Journal of Mass Spectrometry</i> , 2013, 48, 616-625.	0.7	45
138	Host Genetics and HIV-1: The Final Phase?. <i>PLoS Pathogens</i> , 2010, 6, e1001033.	2.1	44
139	Single-cell analysis identifies cellular markers of the HIV permissive cell. <i>PLoS Pathogens</i> , 2017, 13, e1006678.	2.1	44
140	ZNRD1 (Zinc Ribbon Domain-Containing 1) Is a Host Cellular Factor That Influences HIV-1 Replication and Disease Progression. <i>Clinical Infectious Diseases</i> , 2010, 50, 1022-1032.	2.9	42
141	Entry of Polarized Effector Cells into Quiescence Forces HIV Latency. <i>MBio</i> , 2019, 10, .	1.8	41
142	Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. <i>Aids</i> , 2001, 15, 1081-1082.	1.0	41
143	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study. <i>Aids</i> , 2001, 15, 1793-1800.	1.0	39
144	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2959-2966.	1.4	39

#	ARTICLE	IF	CITATIONS
145	Protection from HIV-1 Infection of Primary Cd4 T Cells by Ccr5 Silencing is Effective for the Full Spectrum of Ccr5 Expression. <i>Antiviral Therapy</i> , 2003, 8, 373-377.	0.6	39
146	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
147	Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring. <i>Antiviral Therapy</i> , 2011, 16, 189-197.	0.6	38
148	A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. <i>Human Molecular Genetics</i> , 2013, 22, 1903-1910.	1.4	38
149	Identification of Siglec-1 null individuals infected with HIV-1. <i>Nature Communications</i> , 2016, 7, 12412.	5.8	38
150	Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. <i>Current HIV/AIDS Reports</i> , 2006, 3, 118-125.	1.1	37
151	Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. <i>Aids</i> , 2000, 14, 791-799.	1.0	36
152	Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3226-3232.	1.4	36
153	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016, 18, 814-822.	1.1	36
154	SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2676-2678.	4.8	36
155	Individualising HIV treatment—pharmacogenetics and immunogenetics. <i>Lancet, The</i> , 2002, 359, 722-723.	6.3	35
156	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. <i>Antiviral Therapy</i> , 2007, 12, 1157-1164.	0.6	35
157	Polymorphisms, Resistance and Drug Response: Beyond Subtype-B HIV-1. <i>Antiviral Therapy</i> , 2004, 9, 1-1.	0.6	35
158	The Characteristics of Heterozygous Protein Truncating Variants in the Human Genome. <i>PLoS Computational Biology</i> , 2015, 11, e1004647.	1.5	34
159	Silencing of both β -TrCP1 and HOS (β -TrCP2) Is Required To Suppress Human Immunodeficiency Virus Type 1 Vpu-Mediated CD4 Down-Modulation. <i>Journal of Virology</i> , 2007, 81, 1502-1505.	1.5	33
160	Functional characterization of 3D protein structures informed by human genetic diversity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8960-8965.	3.3	33
161	HIV-1 elite controllers: Beware of super-infections. <i>Journal of Clinical Virology</i> , 2010, 47, 376-378.	1.6	32
162	Analysis of Stop-Gain and Frameshift Variants in Human Innate Immunity Genes. <i>PLoS Computational Biology</i> , 2014, 10, e1003757.	1.5	32

#	ARTICLE	IF	CITATIONS
163	Single-Cell Genomics for Virology. <i>Viruses</i> , 2016, 8, 123.	1.5	32
164	Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a caseâ€“control study from the Swiss HIV Cohort. <i>Aids</i> , 2002, 16, 381-385.	1.0	31
165	Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women. <i>Antiviral Therapy</i> , 2013, 18, 171-182.	0.6	31
166	New Insights into the Genetic Basis of Mongeâ€™s Disease and Adaptation to High-Altitude. <i>Molecular Biology and Evolution</i> , 2017, 34, 3154-3168.	3.5	31
167	Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. <i>Aids</i> , 2000, 14, 2145-2151.	1.0	30
168	Genomics of hostâ€“pathogen interactions. <i>Current Opinion in Immunology</i> , 2014, 30, 32-38.	2.4	30
169	Toxicogenetics of Antiretroviral Therapy: Genetic Factors that Contribute to Metabolic Complications. <i>Antiviral Therapy</i> , 2007, 12, 999-1014.	0.6	30
170	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients. <i>Aids</i> , 2004, 18, 1521-1527.	1.0	29
171	Establishing the involvement of the novel gene <i>AGBL5</i> in retinitis pigmentosa by whole genome sequencing. <i>Physiological Genomics</i> , 2016, 48, 922-927.	1.0	29
172	Discontinuing or withholding primary prophylaxis against <i>Mycobacterium avium</i> in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2000, 14, 1409-1412.	1.0	28
173	<i>HLA-B*47:01</i> Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 1921-1925.	2.9	28
174	Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control. <i>PLoS Computational Biology</i> , 2017, 13, e1005339.	1.5	28
175	Acetaminophen (Paracetamol) Use Modifies the Sulfation of Sex Hormones. <i>EBioMedicine</i> , 2018, 28, 316-323.	2.7	28
176	Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. <i>Aids</i> , 2002, 16, 1982-1983.	1.0	28
177	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	0.6	28
178	Idiopathic Granulomatosis Manifesting as Fever of Unknown Origin. <i>Mayo Clinic Proceedings</i> , 1989, 64, 44-50.	1.4	27
179	Consistent Effects of TSG101 Genetic Variability on Multiple Outcomes of Exposure to Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 6757-6763.	1.5	27
180	Antiretroviral Activity of Ancestral TRIM5 β . <i>Journal of Virology</i> , 2008, 82, 2089-2096.	1.5	27

#	ARTICLE	IF	CITATIONS
181	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. <i>Drug Metabolism and Disposition</i> , 2015, 44, 151-161.	1.7	27
182	Virological and immunological characteristics of HIV treatment failure. <i>Aids</i> , 2000, 14, 1767-1774.	1.0	26
183	Discontinuation of primary prophylaxis in HIV-infected patients at high risk of <i>Pneumocystis carinii</i> pneumonia: prospective multicentre study. <i>Aids</i> , 2001, 15, 501-507.	1.0	26
184	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.	2.9	26
185	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1573-1581.	1.3	25
186	Unique Spectrum of Activity of Prosimian TRIM5 α against Exogenous and Endogenous Retroviruses. <i>Journal of Virology</i> , 2011, 85, 4173-4183.	1.5	25
187	Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. <i>Liver International</i> , 2018, 38, 619-626.	1.9	25
188	Treating medical data as a durable asset. <i>Nature Genetics</i> , 2020, 52, 1005-1010.	9.4	25
189	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. <i>Cell</i> , 2022, 185, 2279-2291.e17.	13.5	25
190	Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 335-336.	0.8	24
191	Reconciling Utility with Privacy in Genomics. , 2014, , .		24
192	Proteo-Transcriptomic Dynamics of Cellular Response to HIV-1 Infection. <i>Scientific Reports</i> , 2019, 9, 213.	1.6	24
193	Infectious diseases not immune to genome-wide association. <i>Nature Genetics</i> , 2010, 42, 731-732.	9.4	23
194	Counteraction of HLA-C-Mediated Immune Control of HIV-1 by Nef. <i>Journal of Virology</i> , 2010, 84, 7300-7311.	1.5	23
195	Impact of Phenotype Definition on Genome-Wide Association Signals: Empirical Evaluation in Human Immunodeficiency Virus Type 1 Infection. <i>American Journal of Epidemiology</i> , 2011, 173, 1336-1342.	1.6	23
196	Host Genes Important to HIV Replication and Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007203-a007203.	2.9	23
197	Exploring viral infection using single-cell sequencing. <i>Virus Research</i> , 2017, 239, 55-68.	1.1	23
198	MDR1 Genetic Polymorphism Does Not Modify either Cell Permissiveness to HIV-1 or Disease Progression before Treatment. <i>Journal of Infectious Diseases</i> , 2004, 189, 583-586.	1.9	22

#	ARTICLE	IF	CITATIONS
199	Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. <i>Pharmacogenomics</i> , 2010, 11, 587-594.	0.6	22
200	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	1.4	22
201	Advances in Genomics for Drug Development. <i>Genes</i> , 2020, 11, 942.	1.0	22
202	Limits to potent antiretroviral therapy. <i>Reviews in Medical Virology</i> , 2000, 10, 385-393.	3.9	21
203	A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. <i>Aids</i> , 2003, 17, 1487-1492.	1.0	21
204	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. <i>PLoS ONE</i> , 2012, 7, e29186.	1.1	21
205	Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. <i>PLoS ONE</i> , 2012, 7, e31928.	1.1	21
206	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 212, 578-584.	1.9	20
207	Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. <i>EBioMedicine</i> , 2015, 2, 706-712.	2.7	20
208	Genetic Diversity of EBV-Encoded LMP1 in the Swiss HIV Cohort Study and Implication for NF- κ B Activation. <i>PLoS ONE</i> , 2012, 7, e32168.	1.1	20
209	Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. <i>Antiviral Therapy</i> , 2007, 12, 1157-64.	0.6	20
210	Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients?. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 332-338.	1.0	19
211	Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. <i>Aids</i> , 2014, 28, 1261-1272.	1.0	18
212	Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. <i>Aids</i> , 2002, 16, 1171-1176.	1.0	17
213	Genomic Approaches to the Study of HIV-1 Acquisition. <i>Journal of Infectious Diseases</i> , 2010, 202, S382-S386.	1.9	17
214	Innate immune defects in HIV permissive cell lines. <i>Retrovirology</i> , 2016, 13, 43.	0.9	17
215	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e18578.	1.1	16
216	The role of tripartite motif family members in mediating susceptibility to HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 180-186.	1.5	16

#	ARTICLE	IF	CITATIONS
217	Development of a Molecular Typing Method for <i>Pneumocystis carinii</i> sp.f. hominis. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 34S-34S.	0.8	15
218	Inteins in mycobacterial GyrA are a taxonomic character. <i>Microbiology (United Kingdom)</i> , 1998, 144, 589-591.	0.7	15
219	Adaptation, co-evolution, and human susceptibility to HIV-1 infection. <i>Infection, Genetics and Evolution</i> , 2005, 5, 327-334.	1.0	15
220	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 609-622.	1.5	15
221	Low Incidence of Community-Acquired Pneumonia among Human Immunodeficiency Virus-Infected Patients after Interruption of <i>Pneumocystis carinii</i> Pneumonia Prophylaxis. <i>Clinical Infectious Diseases</i> , 2003, 36, 917-921.	2.9	14
222	Whole Genome Sequencing Revealed Mutations in Two Independent Genes as the Underlying Cause of Retinal Degeneration in an Ashkenazi Jewish Pedigree. <i>Genes</i> , 2017, 8, 210.	1.0	14
223	Retroviruses As Myeloid Cell Riders: What Natural Human Siglec-1 Knockouts Tell Us About Pathogenesis. <i>Frontiers in Immunology</i> , 2017, 8, 1593.	2.2	14
224	Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlanders. <i>European Journal of Human Genetics</i> , 2019, 27, 150-159.	1.4	14
225	Regulatory genome variants in human susceptibility to infection. <i>Human Genetics</i> , 2020, 139, 759-768.	1.8	14
226	The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-131) is dispensable for the virus in vitro. <i>Journal of General Virology</i> , 2004, 85, 921-927.	1.3	13
227	Genomic determinants of the efficiency of internal ribosomal entry sites of viral and cellular origin. <i>Nucleic Acids Research</i> , 2008, 36, 6918-6925.	6.5	13
228	Evolutionary genomics and HIV restriction factors. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 79-83.	1.5	13
229	Mycobacterial genome structure (minireview). <i>Electrophoresis</i> , 1998, 19, 573-576.	1.3	12
230	Bioinformatics and HIV Latency. <i>Current HIV/AIDS Reports</i> , 2015, 12, 97-106.	1.1	12
231	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipatrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.	1.9	11
232	Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. <i>Blood Advances</i> , 2018, 2, 2419-2429.	2.5	11
233	IFT88 mutations identified in individuals with non-syndromic recessive retinal degeneration result in abnormal ciliogenesis. <i>Human Genetics</i> , 2018, 137, 447-458.	1.8	11
234	Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. <i>Aids</i> , 2004, 18, 356-358.	1.0	10

#	ARTICLE	IF	CITATIONS
235	The mixed blessing of interferon. <i>Nature</i> , 2014, 511, 537-538.	13.7	10
236	Dynamics of an Aging Genome. <i>Cell Metabolism</i> , 2016, 23, 949-950.	7.2	9
237	Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12046.	5.5	9
238	Spare post-exposure prophylaxis with round-the-clock HIV testing of the source patient. <i>Aids</i> , 2001, 15, 2451-2452.	1.0	9
239	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. <i>Chimia</i> , 2012, 66, 291-295.	0.3	8
240	Transfer transcriptomic signatures for infectious diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
241	On genomics, kin, and privacy. <i>F1000Research</i> , 2014, 3, 80.	0.8	8
242	Does tenofovir influence efavirenz pharmacokinetics?. <i>Antiviral Therapy</i> , 2007, 12, 115-8.	0.6	8
243	Typing of <i>Pneumocystis carinii</i> sp.f. <i>hominis</i> by PCR-SSCP of Four Genomic Regions. <i>Journal of Eukaryotic Microbiology</i> , 1997, 44, 16s-16s.	0.8	7
244	Host factors associated with outcome from primary human immunodeficiency virus-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 28-35.	1.5	7
245	A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. <i>Blood</i> , 2011, 118, 5401-5408.	0.6	7
246	HIV-1 host interactions: integration of large-scale datasets. <i>F1000 Biology Reports</i> , 2009, 1, 71.	4.0	7
247	HIV Lipoatrophy and Mosquito Bites. <i>Clinical Infectious Diseases</i> , 2002, 34, 288-289.	2.9	6
248	Interactions of Processed Nef (58-206) with Virion Proteins of HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 399-407.	0.5	6
249	Efavirenz intoxication due to a new CYP2B6 constellation. <i>Antiviral Therapy</i> , 2013, 18, 735-738.	0.6	6
250	Rethinking the medical record. <i>Lancet, The</i> , 2018, 391, 1013.	6.3	6
251	Machine Learning to Decode Genomics. <i>Clinical Chemistry</i> , 2020, 66, 45-47.	1.5	6
252	State of genomics and epigenomics research in the perspective of HIV cure. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 176-181.	1.5	5

#	ARTICLE	IF	CITATIONS
253	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. <i>Antiviral Therapy</i> , 2015, 20, 261-269.	0.6	5
254	Integrating metabolomics with genomics. <i>Pharmacogenomics</i> , 2018, 19, 1377-1381.	0.6	5
255	Impaired absorption of rifabutin by concomitant administration of didanosine. <i>Aids</i> , 2001, 15, 2203-2204.	1.0	5
256	Analysis of Brugada syndrome loci reveals that fine-mapping clustered GWAS hits enhances the annotation of disease-relevant variants. <i>Cell Reports Medicine</i> , 2021, 2, 100250.	3.3	4
257	Identifying Safety Concerns from Genetic Data: Lessons from the Development of CCR5 Inhibitors. <i>Antiviral Therapy</i> , 2007, 12, 147-148.	0.6	4
258	Host polymorphism in steps of the HIV-1 lifecycle after entry and other genetic variants influencing HIV-1 pathogenesis. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 232-240.	1.5	3
259	European Genetic Diversity and Susceptibility to Pathogens. <i>Human Heredity</i> , 2013, 76, 187-193.	0.4	3
260	Simulating patient matching to clinical trials using a property rights blockchain. <i>Digital Medicine</i> , 2020, 6, 44.	0.1	2
261	Genomics of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 77-78.	1.5	1
262	Fine population structure analysis method for genomes of many. <i>Scientific Reports</i> , 2017, 7, 12608.	1.6	1
263	Response to Whiffin et al.. <i>American Journal of Human Genetics</i> , 2019, 104, 186.	2.6	1
264	<sc>MP&Nerf</sc>: A massively parallel method for accelerating protein structure reconstruction from internal coordinates. <i>Journal of Computational Chemistry</i> , 2022, 43, 74-78.	1.5	1
265	HIV Susceptibility Testing â€“ Time for Standards. <i>Antiviral Therapy</i> , 2004, 9, 463-464.	0.6	1
266	Resistance to New Anti-HIV Agents: Problems in the Pathway of Drug Registration. <i>Antiviral Therapy</i> , 2005, 10, 867-872.	0.6	1
267	Nucleic acid amplification methods in diagnostic virology. <i>Journal of Microbiological Methods</i> , 1995, 23, 31-39.	0.7	0
268	HIV epidemiology and treatment â€“ 1999. <i>Ocular Immunology and Inflammation</i> , 1999, 7, 129-132.	1.0	0